Vaxcyte (NASDAQ:PCVX) Stock: Insider Jim Wassil Sells 2,250 Shares

Vaxcyte, Inc. (NASDAQ:PCVX) EVP Jim Wassil sold 2,250 shares of Vaxcyte stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $56.67, for a total value of $127,507.50. Following the completion of the transaction, the executive vice president directly owned 145,435 shares of the company’s stock, valued at $8,241,801.45. This represents a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jim Wassil also recently made the following trade(s):

• On Wednesday, September 9th, Jim Wassil sold 1,334 shares of Vaxcyte stock. The stock was sold at an average price of $59.52, for a total transaction of $79,399.68.
• On Friday, September 4th, Jim Wassil sold 1,381 shares of Vaxcyte stock. The shares were sold at an average price of $61.16, for a total transaction of $84,461.96.
• On Tuesday, September 1st, Jim Wassil sold 3,477 shares of Vaxcyte stock. The stock was sold at an average price of $61.07, for a total transaction of $212,340.39.
• On Monday, August 3rd, Jim Wassil sold 2,250 shares of Vaxcyte stock. The shares were sold at an average price of $53.86, for a total transaction of $121,185.00.

Vaxcyte Stock Up 0.8%

PCVX stock traded up $0.43 during trading on Friday, hitting $56.48. The company had a trading volume of 2,399,621 shares, compared to its average volume of 1,387,746. The firm has a 50-day moving average price of $58.63 and a 200-day moving average price of $56.18. Vaxcyte, Inc. has a 12 month low of $39.87 and a 12 month high of $65.00. The stock has a market cap of $8.40 billion, a price-to-earnings ratio of -7.40 and a beta of 1.23.

Vaxcyte (NASDAQ:PCVX) last released its earnings results on Wednesday, August 5th. The company reported ($1.97) EPS for the quarter, beating the consensus estimate of ($2.06) by $0.09. During the same period last year, the firm earned ($1.22) earnings per share. Equities analysts expect that Vaxcyte, Inc. will post -7.6 EPS for the current year.

Institutional Investors Weigh In On Vaxcyte

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. IFP Advisors Inc increased its position in Vaxcyte by 72.8% during the second quarter. IFP Advisors Inc now owns 560 shares of the company’s stock worth $33,000 after buying an additional 236 shares during the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Vaxcyte by 33.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock valued at $34,000 after buying an additional 184 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its position in shares of Vaxcyte by 1,924.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 830 shares of the company’s stock valued at $38,000 after buying an additional 789 shares during the last quarter. Capital Advisors Ltd. LLC bought a new position in shares of Vaxcyte during the 1st quarter worth approximately $58,000. Finally, Eurizon Capital SGR S.p.A. bought a new position in shares of Vaxcyte during the 4th quarter worth approximately $63,000. 96.78% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on PCVX. Needham & Company LLC reiterated a “buy” rating and set a $110.00 price target on shares of Vaxcyte in a research report on Friday, September 25th. Bank of America reduced their price objective on shares of Vaxcyte from $133.00 to $130.00 and set a “buy” rating on the stock in a research note on Monday. Zacks Research upgraded shares of Vaxcyte from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 12th. Wall Street Zen upgraded Vaxcyte from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a report on Monday, July 6th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $104.40.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing vaccines to help prevent serious bacterial infections. The company uses its cell-free protein synthesis and advanced conjugation technologies to design vaccines intended to provide broad and durable protection while addressing limitations of existing vaccine products.

Vaxcyte’s lead programs are pneumococcal conjugate vaccine candidates, including VAX-24 and VAX-31, which are designed to target a broad range of pneumococcal serotypes.